Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biohaven Pharmaceutical Holding Ltd
(NY:
BHVN
)
145.31
-0.40 (-0.27%)
Official Closing Price
Updated: 6:30 PM EDT, Jul 1, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
880,611
Open
145.44
Bid (Size)
144.70 (5)
Ask (Size)
145.70 (1)
Prev. Close
145.71
Today's Range
145.10 - 145.92
52wk Range
79.01 - 151.51
Shares Outstanding
65,401,228
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
Top News
More News
Hopeful Golden Cross Forms On Biohaven Pharma Hldgs's Chart
June 23, 2022
If history is any guide, there may be good fortune ahead for shares of Biohaven Pharma Hldgs (NYSE:BHVN). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish...
Via
Benzinga
Looking Into Biohaven Pharmaceutical's Return On Capital Employed
June 10, 2022
According to data from Benzinga Pro, during Q1, Biohaven Pharmaceutical's (NYSE:BHVN) reported sales totaled $318.85 million. Despite a 41.43% increase in earnings, the company posted a loss of $116.90...
Via
Benzinga
Performance
YTD
+4.42%
+4.42%
1 Month
+1.10%
+1.10%
3 Month
+22.55%
+22.55%
6 Month
+5.09%
+5.09%
1 Year
+49.68%
+49.68%
More News
Read More
3 Biotech Stocks to Buy Before They Boom
June 01, 2022
Via
InvestorPlace
Pfizer's Nearly $7 Billion Acquisition Of Arena Pharma Just Paid Off In A Big Way
May 24, 2022
Via
Investor's Business Daily
Biohaven's Neurological Disease Candidate Flunks In Late-Stage Study
May 23, 2022
Via
Benzinga
BIOHAVEN INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Biohaven Pharmaceutical Holding Company Ltd. - BHVN
May 17, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
Recap: Biohaven Pharma Hldgs Q1 Earnings
May 10, 2022
Via
Benzinga
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
May 16, 2022
Via
Benzinga
Stock Market Tries To Bounce From Fresh 2022 Lows; Tesla CEO Elon Musk Puts Twitter Deal 'On Hold': Weekly Review
May 13, 2022
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2022
May 11, 2022
Via
Benzinga
103 Biggest Movers From Yesterday
May 11, 2022
Via
Benzinga
Why Is Biohaven Pharmaceutical (BHVN) Stock Up Today?
May 10, 2022
Via
InvestorPlace
Mid-Afternoon Market Update: Nasdaq Jumps Over 200 Points; Crude Oil Down 3%
May 10, 2022
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
May 10, 2022
Via
Benzinga
Dow Reverses Morning Rally as Recession Fears Swirl
May 10, 2022
Via
Talk Markets
Mid-Day Market Update: U.S. Stocks Turn Lower; Biohaven Pharmaceutical Shares Jump
May 10, 2022
Via
Benzinga
77 Stocks Moving In Tuesday's Mid-Day Session
May 10, 2022
Via
Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
May 10, 2022
Via
Benzinga
Pfizer Buys Biohaven In A $12 Billion Deal That 'Couldn't Have Come At A Better Time'
May 10, 2022
Via
Investor's Business Daily
Pfizer Acquires This Migraine Drug Maker For $11B: What Investors Need To Know
May 10, 2022
Via
Benzinga
BHVN Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Biohaven Pharmaceutical Holding Company Ltd. Is Fair to Shareholders
May 10, 2022
From
Halper Sadeh LLP
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
May 10, 2022
Via
Benzinga
Pfizer to Acquire Biohaven Pharmaceuticals
May 10, 2022
From
Pfizer Inc.
Via
Business Wire
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
April 27, 2022
Via
Benzinga
European Commission Granted Marketing Authorization For Pfizer and Biohaven's VYDURA® (Rimegepant) For Migraine
April 27, 2022
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.